Beijing Konruns Pharmaceutical Co.,Ltd.
603590.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.93B
Close$
$6.68
77.7% downside
Current Fair Value
77.7% downsideOvervalued by 77.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.93 Billion |
|---|---|
| Enterprise Value | $4.96 Billion |
| Dividend Yield | $0.35 (1.13%) |
| Earnings per Share | $1.05 |
| Beta | 0.45 |
| Outstanding Shares | 157,011,673 |
Return
| Return on Equity | 5.36% |
|---|---|
| Return on Assets | 4.14% |
| Return on Invested Capital | 5.11% |
Valuation & Multiples
| P/E Ratio | 28.69 |
|---|---|
| PEG | 681.13 |
| Price to Sales | 6.0 |
| Price to Book Ratio | 1.36 |
| Enterprise Value to Revenue | 5.41 |
| Enterprise Value to EBIT | 27.14 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Beijing Konruns Pharmaceutical Co.,Ltd.
793 employees
CEO: Zhanqi Niu Beijing Konruns Pharmaceutical Co.,Ltd., a Chinese company established in 2003 and based in Beijing, focuses on the discovery, production, and distribution of various pharmaceutical items. Among its key offerings is Su Ling, a hemaggluti...